{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:54:00Z","timestamp":1794920040496,"version":"4.9.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40261-022-01150-w","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T10:12:06Z","timestamp":1651831926000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Management of Pharmacologic Adverse Effects in Advanced Liver Disease"],"prefix":"10.1007","volume":"42","author":[{"given":"Miren","family":"Garc\u00eda-Cort\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garc\u00eda-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"4","key":"1150_CR1","first-page":"172","volume":"39","author":"M Garc\u00eda-Cort\u00e9s","year":"2016","unstructured":"Garc\u00eda-Cort\u00e9s M, Gonz\u00e1lez-Amores Y, Casado-Bernab\u00e9u A, Ortega-Alonso A, Romero-P\u00e9rez E, Lara-Romero C. Management of routine use drugs in advanced chronic liver disease. RAPD Online. 2016;39(4):172\u201383.","journal-title":"RAPD Online."},{"issue":"12","key":"1150_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","volume":"64","author":"RK Verbeeck","year":"2008","unstructured":"Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147\u201361. https:\/\/doi.org\/10.1007\/s00228-008-0553-z.","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"1150_CR3","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2165\/11635500-000000000-00000","volume":"72","author":"M Bosilkovska","year":"2012","unstructured":"Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J. Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs. 2012;72(12):1645\u201369. https:\/\/doi.org\/10.2165\/11635500-000000000-00000.","journal-title":"Drugs"},{"issue":"Espec Congr 1","key":"1150_CR4","first-page":"28","volume":"35","author":"RJ Andrade","year":"2012","unstructured":"Andrade RJ, Lucena MI. \u00bfC\u00f3mo usar correctamente los f\u00e1rmacos en pacientes con enfermedades hep\u00e1ticas? Gastroenterol Hepatol. 2012;35(Espec Congr 1):28\u201337.","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"1150_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0168-8278(95)80428-5","volume":"22","author":"MI Lucena","year":"1995","unstructured":"Lucena MI, Andrade RJ, Cabello MR, Hidalgo R, Gonzalez-Correa JA, Sanchez de la Cuesta F. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 1995;22(2):189\u201396. https:\/\/doi.org\/10.1016\/0168-8278(95)80428-5.","journal-title":"J Hepatol"},{"issue":"1","key":"1150_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0016-5085(82)90129-9","volume":"82","author":"J Cabrera","year":"1982","unstructured":"Cabrera J, Arroyo V, Ballesta AM, Rimola A, Gual J, Elena M, et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology. 1982;82(1):97\u2013105.","journal-title":"Gastroenterology"},{"issue":"4","key":"1150_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4321\/s1130-01082012000400001","volume":"104","author":"RJ Andrade","year":"2012","unstructured":"Andrade RJ, Lucena MI. Drugs prescription in patients with chronic liver disease: rules for adjusting doses and beyond. Rev Esp Enferm Dig. 2012;104(4):161\u20134. https:\/\/doi.org\/10.4321\/s1130-01082012000400001.","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"1150_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jhep.2015.04.004","volume":"63","author":"C Elia","year":"2015","unstructured":"Elia C, Graupera I, Barreto R, Sola E, Moreira R, Huelin P, et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: a case-control study. J Hepatol. 2015;63(3):593\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2015.04.004.","journal-title":"J Hepatol"},{"issue":"5","key":"1150_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hep4.1334","volume":"3","author":"KL Hayward","year":"2019","unstructured":"Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, et al. Medication-related problems in outpatients with decompensated cirrhosis: opportunities for harm prevention. Hepatol Commun. 2019;3(5):620\u201331. https:\/\/doi.org\/10.1002\/hep4.1334.","journal-title":"Hepatol Commun"},{"issue":"6","key":"1150_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","volume":"28","author":"F Delc\u00f2","year":"2005","unstructured":"Delc\u00f2 F, Tchambaz L, Schlienger R, Drewe J, Krahenbuhl S. Dose adjustment in patients with liver disease. Drug Saf. 2005;28(6):529\u201345. https:\/\/doi.org\/10.2165\/00002018-200528060-00005.","journal-title":"Drug Saf"},{"issue":"12","key":"1150_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/apt.12324","volume":"37","author":"JH Lewis","year":"2013","unstructured":"Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis\u2014a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132\u201356. https:\/\/doi.org\/10.1111\/apt.12324.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1150_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00228-002-0474-1","volume":"58","author":"MI Lucena","year":"2002","unstructured":"Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, de la Cuesta FS. Spanish Collaborative Study Group on Therapeutic Management In Liver Disease. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435\u201340. https:\/\/doi.org\/10.1007\/s00228-002-0474-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1150_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31548","author":"MJ Thomson","year":"2020","unstructured":"Thomson MJ, Lok ASF, Tapper EB. Appropriate and potentially inappropriate medication use in decompensated cirrhosis. Hepatology. 2020. https:\/\/doi.org\/10.1002\/hep.31548.","journal-title":"Hepatology"},{"issue":"10","key":"1150_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012991","volume":"6","author":"RA Weersink","year":"2016","unstructured":"Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, et al. Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion. BMJ Open. 2016;6(10): e012991. https:\/\/doi.org\/10.1136\/bmjopen-2016-012991.","journal-title":"BMJ Open"},{"issue":"6","key":"1150_CR15","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40264-017-0635-x","volume":"41","author":"RA Weersink","year":"2018","unstructured":"Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis. Drug Saf. 2018;41(6):603\u201313. https:\/\/doi.org\/10.1007\/s40264-017-0635-x.","journal-title":"Drug Saf"},{"issue":"4","key":"1150_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40264-018-0744-1","volume":"42","author":"RA Weersink","year":"2019","unstructured":"Weersink RA, Taxis K, Drenth JPH, Houben E, Metselaar HJ, Borgsteede SD. Prevalence of drug prescriptions and potential safety in patients with cirrhosis: a retrospective real-world study. Drug Saf. 2019;42(4):539\u201346. https:\/\/doi.org\/10.1007\/s40264-018-0744-1.","journal-title":"Drug Saf"},{"issue":"12","key":"1150_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/MEG.0000000000001492","volume":"31","author":"M Aghili","year":"2019","unstructured":"Aghili M, Neelathahalli KM. Identifying characteristics of drug-related problems in critically ill patients with decompensated liver cirrhosis. Eur J Gastroenterol Hepatol. 2019;31(12):1569\u201376. https:\/\/doi.org\/10.1097\/MEG.0000000000001492.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"1150_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/clpt.2011.58","volume":"89","author":"GP Aithal","year":"2011","unstructured":"Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806\u201315. https:\/\/doi.org\/10.1038\/clpt.2011.58.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1150_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/hep.28808","volume":"65","author":"I Medina-C\u00e1liz","year":"2017","unstructured":"Medina-C\u00e1liz I, Robles-D\u00edaz M, Lucena MI, Andrade RJ. Drug-induced liver and skin reactions: in need of a consensus definition. Hepatology. 2017;65(1):391. https:\/\/doi.org\/10.1002\/hep.28808.","journal-title":"Hepatology"},{"issue":"11","key":"1150_CR20","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1111\/liv.12834","volume":"35","author":"M Robles-D\u00edaz","year":"2015","unstructured":"Robles-D\u00edaz M, Garc\u00eda-Cort\u00e9s M, Medina-C\u00e1liz I, Gonz\u00e1lez-Jim\u00e9nez A, Gonz\u00e1lez-Grande R, Navarro JM, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int. 2015;35(11):2474\u201382. https:\/\/doi.org\/10.1111\/liv.12834.","journal-title":"Liver Int"},{"issue":"4","key":"1150_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1517\/14740338.3.4.329","volume":"3","author":"RJ Andrade","year":"2004","unstructured":"Andrade RJ, Camargo R, Lucena MI, Gonz\u00e1lez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf. 2004;3(4):329\u201344. https:\/\/doi.org\/10.1517\/14740338.3.4.329.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"1150_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C. Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323\u201330. https:\/\/doi.org\/10.1016\/0895-4356(93)90101-6.","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"1150_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology. 2015;148(7):1340-52 e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006.","journal-title":"Gastroenterology"},{"key":"1150_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.029","author":"C Stephens","year":"2021","unstructured":"Stephens C, Robles-D\u00edaz M, Medina-C\u00e1liz I, Garc\u00eda-Cortes M, Ortega-Alonso A, Sanabria-Cabrera J, et al. Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. J Hepatol. 2021. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.029.","journal-title":"J Hepatol"},{"issue":"6","key":"1150_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver","year":"2019","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222\u201361. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014.","journal-title":"J Hepatol"},{"issue":"2","key":"1150_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","volume":"115","author":"ED Miller","year":"2020","unstructured":"Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonz\u00e1lez GM, Blechacz B, Naing A, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol. 2020;115(2):251\u201361. https:\/\/doi.org\/10.14309\/ajg.0000000000000398.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1150_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bjornsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58. https:\/\/doi.org\/10.1038\/s41572-019-0105-0.","journal-title":"Nat Rev Dis Primers"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01150-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T09:14:04Z","timestamp":1655457244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01150-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"assertion":[{"value":"24 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as a part of a journal supplement wholly funded by Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure statement"}},{"value":"Eisai funded the writing assistance provided by Springer Healthcare Ib\u00e9rica SL.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors report no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}